Using ICR strain mice as experimental animals, 0.25% (w/v) ferric ammonium citrate (FAC) was a suitable substitute for 5% (w/v) mucin as a virulence-enhancing (VE) agent in the toxicity test of Vibrio cholerae and the potency assay of cholera vaccine. There was no significant lethal toxicity difference between 0.25% FAC and 5% mucin as VE agents on Vibrio cholerae in mice. By using 0.25% FAC as a VE agent in estimating the potency of cholera vaccine, the relative potency (R.P.) of the tested cholera vaccine (Inaba) to the reference cholera vaccine (Inaba) was 0.896 +/- 0.208, the variation coefficient (V.C.) was 0.232, the correlation between the immune dose and the ratio of mouse death (r2) was 0.9932; for the cholera vaccine (Ogawa), R.P. was 1.373 +/- 0.366, V.C. was 0.266 and r2 was 0.8231. There was no significant difference between 5% mucin and 0.25% FAC used as VE agents in potency assay of cholera vaccine.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cholera in conflict: outbreak analysis and response lessons from Gadaref state, Sudan (2023-2024).
BMC Public Health
March 2025
Federal, Ministry of Health, Khartoum, Sudan.
Background: Cholera is an acute, severe, illness caused by infection with Vibrio cholerae. Cholera outbreaks are closely linked to armed conflicts and humanitarian emergencies. This study describes the cholera outbreak amidst conflict in Gadaref state, discusses the possible factors mediated its spread and proposes future improvements in preparedness and response measures.
View Article and Find Full Text PDFComputational Development of Transmission-Blocking Vaccine Candidates Based on Fused Antigens of Pre- and Post-fertilization Gametocytes Against .
Bioinform Biol Insights
March 2025
Discipline of Genetics, School of Life Sciences, College of Agriculture, Engineering and Sciences, University of KwaZulu-Natal, Durban, South Africa.
is the most fatal species of malaria parasites in humans. Attempts at developing vaccines against the malaria parasites have not been very successful even after the approval of the RTS, S/AS01 vaccine. There is a continuous need for more effective vaccines including sexual-stage antigens that could block the transmission of malaria parasites between mosquitoes and humans.
View Article and Find Full Text PDFChallenges with achieving and maintaining oral cholera vaccine coverage: insights from serial cross-sectional representative surveys in a cholera-endemic community in the Democratic Republic of the Congo.
BMJ Public Health
January 2025
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Background: We conducted three serial cross-sectional representative surveys after a mass cholera vaccination campaign in Uvira, Democratic Republic of the Congo to (1) estimate the vaccination coverage and explore heterogeneity by geographic and demographic factors; (2) examine barriers and facilitators of vaccine uptake and (3) describe the changes in coverage over time and predict future coverage.
Methods: We collected data on sociodemographics, self-reported vaccination status, population movement and knowledge, attitudes and behaviours related to killed oral cholera vaccines (kOCVs) in August 2021, April 2022 and April 2023, approximately 11, 19 and 30 months postvaccination. We compared the characteristics of participants by vaccination status and explored the potential role of population movement as a cause for low coverage.
Dynamics of global emergency vaccine stockpiles: A systems analysis and application to cholera.
Vaccine
February 2025
Access-To-Medicines Research Centre, KU Leuven, Vlamingenstraat 83, Leuven 3000, Belgium.
Background: The frequency and magnitude of infectious disease outbreaks are expected to rise. Although emergency vaccine stockpiles have emerged as a strategy to hedge against sporadic demand and accelerate response efforts, their long-term management is complex.
Objective: This study investigates the role of global emergency vaccine stockpiles in achieving public health goals over time and underlying health system structures that drive their performance, with an application to cholera.
A VCG-Based Multiepitope Vaccine Incorporating the Cholera Toxin A1 Subunit (MECA) Confers Protective Immunity Against Transcervical Challenge.
Biomedicines
January 2025
Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA.
: We generated a novel recombinant ghost (rVCG)-based subunit vaccine incorporating the A1 subunit of cholera toxin (CTA1) and a multiepitope (CT) antigen (MECA) derived from five chlamydial outer membrane proteins (rVCG-MECA). The ability of this vaccine to protect against a CT transcervical challenge was evaluated. : Female C57BL/6J mice were immunized thrice at two-week intervals with rVCG-MECA or rVCG-gD2 (antigen control) via the intramuscular (IM) or intranasal (IN) route.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!